Handok’s paroxymal nocturnal hemoglobinuria (PNH) treatment Ultomiris (ravulizumab) is getting closer to the National Health Insurance (NHI) reimbursement.

On Mar. 4, the Health Insurance Review and Assessment Service (HIRA) convened a second meeting of the year for the Drug Reimbursement Evaluation Committee (DREC) and deliberated listing six items, such as Ultomiris, Sanofi-Aventis Korea’s Praluent (alirocumab) pen injection 75 mg and 100 mg, Kuhnil, Penmix, Boryung Pharmaceutical and Yungjin Pharm’s Pentosin (daptomycin) injection 350 mg and 500 mg.

As a result, the reimbursement for Praluent injection was cleared, but Ultomiris and Pentosin were conditionally passed, where the c